Regeneron Says Trevogrumab Preserves Muscle During GLP-1-Induced Weight Loss

12:39 PM EDT, 10/01/2026 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) reported new results from a phase 2 trial that evaluated trevogrumab for its potential to prevent muscle and lean mass loss during weight loss from GLP-1 drugs. In a predefined MRI analysis, trevogrumab prevented 70% of the muscle loss associated with semaglutide, the company said Thursday in a statement. Patients with low lean mass, a marker of sarcopenia, lost more lean mass on semaglutide and showed greater preservation with trevogrumab. Based on the results, Regeneron plans to start a phase 2 trial combining trevogrumab with GLP-1 therapies in older adults with obesity and low muscle mass or strength. Price: 727.86, Change: -30.41, Percent Change: -4.01